These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34117864)

  • 1. NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease.
    Khan A; Johnson R; Wittmer C; Maile M; Tatsukawa K; Wong JL; Gill MB; Stocking EM; Natala SR; Paulino AD; Bowden-Verhoek JK; Wrasidlo W; Masliah E; Bonhaus DW; Price DL
    Brain; 2021 Dec; 144(12):3692-3709. PubMed ID: 34117864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
    Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
    Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
    Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
    Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Female Sex and Brain-Selective Estrogen Benefit α-Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice.
    Rajsombath MM; Nam AY; Ericsson M; Nuber S
    J Neurosci; 2019 Sep; 39(38):7628-7640. PubMed ID: 31405930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
    Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
    J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced cerebral blood flow in an
    Biju KC; Shen Q; Hernandez ET; Mader MJ; Clark RA
    J Cereb Blood Flow Metab; 2020 Dec; 40(12):2441-2453. PubMed ID: 31856640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
    Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
    Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson's disease.
    Parkhe A; Parekh P; Nalla LV; Sharma N; Sharma M; Gadepalli A; Kate A; Khairnar A
    Neurosci Lett; 2020 Jan; 716():134652. PubMed ID: 31778768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant A53T α-Synuclein Improves Rotarod Performance Before Motor Deficits and Affects Metabolic Pathways.
    Guerreiro PS; Coelho JE; Sousa-Lima I; Macedo P; Lopes LV; Outeiro TF; Pais TF
    Neuromolecular Med; 2017 Mar; 19(1):113-121. PubMed ID: 27535567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
    J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved.
    Flores-Cuadrado A; Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Martinez-Marcos A
    Eur J Neurosci; 2015 Jan; 41(1):137-46. PubMed ID: 25345880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model.
    Scheffold A; Holtman IR; Dieni S; Brouwer N; Katz SF; Jebaraj BM; Kahle PJ; Hengerer B; Lechel A; Stilgenbauer S; Boddeke EW; Eggen BJ; Rudolph KL; Biber K
    Acta Neuropathol Commun; 2016 Aug; 4(1):87. PubMed ID: 27550225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
    George S; Mok SS; Nurjono M; Ayton S; Finkelstein DI; Masters CL; Li QX; Culvenor JG
    J Mol Neurosci; 2010 Oct; 42(2):243-54. PubMed ID: 20464527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.